Oral Tucatinib vs Placebo added to Herceptin/Capecitabine #SABCS19 #Her2Climb 612 Volunteers participated, 14 mon F/U, ~4 lines prior therapy, 47% brain mets
🗣Reduced Risk of progression or death by 46%
In heavily pretreated patients with HER2+ metastatic breast cancer, including those w/ brain metastases, adding tucatinib to trastuzumab and capecitabine results in better progression-free survival & overall survival outcomes than adding placebo. #SABCS19 nej.md/2PqW232